The EPS projection of FibroGen, Inc (NASDAQ:FGEN) for quarter ended 2016-09-30 is $-0.5. A week before, the EPS forecast was $-0.5 against target of $-0.5, a month earlier. This estimate stood at $-0.5 60 days earlier versus forecast of $-0.5 90 days earlier, confirming a deviation of 0%.
FibroGen, Inc (NASDAQ:FGEN) reported that 18 days ago, the positive EPS revisions were 1 and negative revisions at 1.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 1, 2, 0 and 2, respectively.
The downgrade of EPS estimates for FibroGen, Inc (NASDAQ:FGEN) in the preceding 120, 60, 30 and 90 days were 1, 1, 0 and 1, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of FibroGen, Inc (NASDAQ:FGEN) was $-0.5. This projection was computed after accounting 3 calls. As reported on 2016-05-09 the EPS was $-0.45. The change was $0.24, demonstrating a percentage deviation of 34.78%. The projections confirmed a standard deviation of 0.13.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for FibroGen, Inc (NASDAQ:FGEN) stands at $19.287 and the median estimate at $19.325. Almost 4 analysts announced their estimates.
The highest estimate is $24.5 while the lowest target is $14 showing standard deviation of 4.582%.
As many as 4 analysts released sales estimates reised in upside while 4 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 4 revised sales number projection on upside while 4 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 4 hiked sales estimations and 4 reduced sales forecast. FibroGen, Inc (NASDAQ:FGEN) stated that the change in forecast was -43.005%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...